|
|
News for Healthier Living
ESMO 2026: Immunotherapy Combination Extends Survival in Advanced Endometrial Cancer
MADRID, OCTOBER 24, 2026 - An immunotherapy-based regimen combining durvalumab and the PARP inhibitor, olaparib, demonstrated encouraging long-term survival outcomes for patients with advanced or recurrent endometrial cancer, according to new trial results presented by researchers from The University of Texas MD Anderson Cancer Center.
October 24, 2026
October 29 2026October 28 2026October 27 2026October 26 2026October 25 2026October 24 2026October 23 2026October 22 2026October 21 2026October 20 2026October 19 2026October 18 2026October 17 2026October 16 2026
|
|
|
|
|